Webcast CME

 

 

 

 

No Bone Unturned: Unraveling the Biology and Treatment
for Myelodysplastic Syndromes, Myeloproliferative
Neoplasms, Acute Myeloid Leukemia and
Treatment-Related Myeloid Neoplasms



Print this Content

How to Obtain AMA PRA Category 1 Credit

  1. Watch the webcast.
  2. Answer the CME polling questions within the webcast.
  3. Log into your myCME account.
  4. Complete the credit and evaluation form.
  5. Print your personalized CME certificate.
  6. Credit can only be claimed once for this activity.

Technical Requirements



Release Date:   January 8, 2016
Expiration Date:   January 8, 2018

Estimated Time of Completion:  3 hours

Description

The No Bone Unturned: Unraveling the Biology and Treatment for Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Acute Myeloid Leukemia and Treatment-Related Myeloid Neoplasms webcast features a review of disease research and clinical practice regarding the contributions of cytogenetics and molecular genetics to the biology of these disorders. Also identified is the role of novel pharmacologic therapies and innovations with transplantation to improve the care of these patient populations.

Learning Objectives

  1. Describe how research on cytogenetic abnormalities in MDS and MPN has affected scoring systems for assessing risk factors associated with MDS and MPN.
  2. Discuss the clinical implications of cytogenetic and molecular abnormalities on diagnosis and treatment choices in MDS and MPN.
  3. Critically evaluate the population impact from radiation accidents and apply them to the pathogenesis of MDS/MPN and AML.
  4. Define the risks of developing MDS and MPN that are associated with cancer treatments, especially radiation and chemotherapies.
  5. Compare the safety and efficacy data from trials using combination therapies and/or stand-alone therapy and interpret their clinical implications.
  6. Discuss risks and benefits of alternative transplant options (cord blood transplant, reduced intensity transplant, and haplo-transplants) for patients diagnosed with MDS, MPN, or AML.

Target Audience

This educational activity is designed for an international audience including medical oncologists/ hematologists, clinical and translational researchers, and other physicians and allied health care professionals treating patients with MDS and other bone marrow failure diseases. In addition, members of patient advocacy groups will benefit from this program.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Cleveland Clinic Foundation Center for Continuing Education and Aplastic Anemia & MDS International Foundation. The Cleveland Clinic Foundation Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of  3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Activity Director and Faculty

Activity Director

Hetty Carraway, MD, MBA
Department of Hematologic Oncology and Blood Disorders
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH

Faculty

Rafael Bejar, MD, PhD
University of California
San Diego Moores Cancer Center
La Jolla, CA

Rena Buckstein, MD, FRCPC
Sunnybrook Health Science Centre
Toronto, Ontario, Canada

Robert Gale, MD, PhD
Imperial College
London, England

Sudipto Mukherjee, MD, MPH
Cleveland Clinic
Cleveland, OH

Bart Scott, MD
Fred Hutchinson Cancer Research Center
Seattle, WA

John Seymour, MD
Peter MacCallum Cancer Centre
Melbourne, Australia

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship which, in the context of their presentation, could be perceived as a potential conflict of interest:


Rafael Bejar, MD, PhD
  Genoptix, Inc. Consulting
  Intellectual property rights (Royalties or patent sales)
  Membership on Advisory Committee or Review Panels
  Celgene Corporation Consulting
  Membership on Advisory Committee or Review Panels
 
Bart Scott, MD
  Celgene Corporation Consulting
  Membership on advisory committee or review panels
  Teaching and Speaking
 
John Seymour, MD
  Celgene Corporation Membership on advisory committee or review panels
  Teaching and Speaking

The following faculty have indicated they have no relationship which, in the context of their presentation, could be perceived as a potential conflict of interest:

Rena Buckstein, MD, FRCPC
Hetty Carraway, MD, MBA
Robert Gale, MD, PhD
Sudipto Mukherjee, MD, MPH

Acknowledgements

The Cleveland Clinic Foundation Center for Continuing Education
and the Aplastic Anemia & MDS International Foundation
acknowledges educational grants for partial support of this activity from:


Acceleron Pharma
Actinium Pharmaceuticals
Agios Pharmaceuticals, Inc.
Amgen, Inc.
Baxalta
Celgene Corporation
CTI BioPharma Corp.
Gilead Sciences
Onconova Therapeutics, Inc.
Seattle Genetics
Tetralogic Pharmaceuticals

This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education,
Cleveland Clinic’s Taussig Cancer Institute and Aplastic Anemia & MDS International Foundation.